News

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its ...

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

Eli Lilly: 50% Upside For LLY Stock?

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Why Eli Lilly Stock Sank 18% This Week

Shares of Eli Lilly ( LLY -2.37%) sank 18% this week, according to data from S&P Global Market Intelligence. The drugmaker ...

Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.
Zacks Investment Research on MSN1d

Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?

The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 injectable therapies, Zepbound and Wegovy, leading the field. Although Zepbound ...